SecBot SecBot
SECBOTREPLAY Home › Report › TARA

TARA · Protara Therapeutics reported Q1 2026 net loss of $0.31 per share,…

Protara Therapeutics · PRESS-RELEASE filed May 13, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 13, 2026 at 08:00 ET

Protara Therapeutics reported Q1 2026 net loss of $0.31 per share, beating consensus estimates of $0.37 loss, with cash of $177.4M to fund operations into 2028. Pipeline progress includes planned BLA submission for TARA-002 in lymphatic malformations in 2H 2027 and multiple data presentations in May 2026.

  • Q1 2026 net loss $17.8M ($0.31/share) vs consensus $0.37 loss per share
  • Cash, equivalents and marketable securities $177.4M as of March 31, 2026
  • Plan to submit BLA for TARA-002 in LMs in 2H 2027
  • Enrollment completion for BCG-Unresponsive cohort in ADVANCED-2 trial expected 2H 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access